ecce vicit leo

Joined December 2017
;)
$TE Current bull / bear is debating whether $TE is either (bear) a keystone cops level fraud involving former Enron consultants or (bull) one of the best fab operators in the world. The bears have a "top secret" whistleblower that knows about a "secret warehouse" where the “mickey mouse” and extremely basic alleged fraud occurs. The bulls have one of the best accreditation firms doing a site visit and comping it to 500+ other facilities around the world. Let’s see how this plays out;)
3
32
9,103
In May 2026, $ADMA claimed an internal review (which hadn't been announced prior) cleared the Company of improper conduct. Today, July 2026 FOIA logs suggest that $ADMA may be subject to a new, undisclosed SEC investigation. Still short.
NEW: We are short ADMA Biologics $ADMA. We believe the ASCENIV growth story is in reality a story of channel stuffing and an undisclosed related party distributor. Real revenues declined 3% in 2025 vs. 20% reported growth. It's already over. Full report available on our website.
1
1
1
10
8,376
$NVDA CEO Jensen Huang met Tuesday with Commerce Secretary Howard Lutnick as the Trump administration investigates potential violations involving Nvidia chip exports to China, according to a source familiar. axios.com/2026/07/28/nvidia-…
1
1
4
5,759
NEW: We are short Tarsus Pharmaceuticals $TARS, maker of XDEMVY, a $2,000 eyedrop for demodex blepharitis. We think XDEMVY rests on a TARS-funded Medicare copay scheme raising serious Anti-Kickback concerns, real TAM is a fraction of the hype, and $TARS whiffs on '26 FY numbers.
9
4
14
42
50,615
25) Blackstone appears to agree. In May 2025, BX bought Elanco's XDEMVY royalty stream for just $295M, a price that implies, per our sensitivity analysis, peak XDEMVY revenues of $712M to $1.3B - roughly half of what $TARS claims.
1
1
2,551
26/26) We are short $TARS and think shares are headed lower as the Company draws AKS/DoJ scrutiny, XDEMVY revenues peak well below $2B, and 2026 results continue to disappoint. Please see our full report and disclaimers on our website, culperresearch.com
1
1
4
2,346